MedPath

JYP-0015 Advanced Drug Monograph

Published:Jun 19, 2025

Generic Name

JYP-0015

JYP-0015 (ERAS-0015): A Pan-RAS Molecular Glue Poised to Redefine the Treatment of RAS-Mutant Cancers

Executive Summary

JYP-0015, also known as ERAS-0015, is a novel, orally bioavailable, small molecule investigational drug that represents a significant advancement in the field of precision oncology. Developed by Guangzhou JOYO Pharma and subsequently in-licensed by Erasca, Inc., JYP-0015 is a pan-RAS inhibitor that functions as a molecular glue. Its mechanism of action is distinct from first-generation targeted therapies; it is designed to inhibit all three major RAS isoforms (KRAS, NRAS, and HRAS) by inducing the formation of a ternary complex between the active, GTP-bound "ON" state of RAS and the intracellular chaperone protein Cyclophilin A (CypA). This action effectively blocks downstream signaling through the critical RAS/MAPK pathway, which is a primary driver of cellular proliferation and survival in a vast number of human cancers.

RAS mutations, present in approximately 21-30% of all human tumors, have long been considered "undruggable" due to the protein's challenging structural characteristics. While the recent development of allele-specific KRAS G12C inhibitors validated RAS as a viable therapeutic target, their clinical utility is confined to a narrow patient population and is often limited by the rapid onset of resistance. JYP-0015 aims to overcome these limitations by targeting a broad spectrum of RAS mutations and isoforms, potentially addressing a patient population of nearly 2.7 million new diagnoses annually worldwide.

Preclinical data presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting positions ERAS-0015 as a potential best-in-class agent. These studies highlight a significantly higher binding affinity for CypA (8- to 21-fold greater) and consequently higher potency (approximately 5-fold greater) compared to its most advanced competitor, RMC-6236 (daraxonrasib). This superior preclinical profile suggests the potential for a wider therapeutic window and robust anti-tumor activity at lower, more tolerable doses.

Erasca, Inc. has strategically pivoted its entire pipeline to focus on its newly acquired RAS-targeting franchise, underscoring its conviction in the potential of JYP-0015. The company has initiated a Phase I/II clinical trial, known as STAR or AURORAS-1 (NCT06895031), to evaluate the safety, pharmacokinetics, and anti-tumor activity of JYP-0015 in patients with advanced solid tumors harboring RAS mutations. The trial will enroll an estimated 210 patients across cohorts including pancreatic, colorectal, and non-small cell lung cancer, with initial monotherapy data anticipated in 2026.

The ultimate success of JYP-0015 will likely depend not only on its monotherapy activity but also on its performance in combination regimens designed to overcome adaptive resistance. Preclinical evidence strongly supports combinations with immunotherapy and other MAPK pathway inhibitors. The key challenges ahead include translating its compelling preclinical potency into a differentiated clinical profile in terms of efficacy and safety, and navigating a rapidly evolving and competitive landscape. If successful, JYP-0015 has the potential to become a foundational therapy for a wide range of RAS-driven cancers, addressing one of the most significant unmet needs in oncology.

I. The RAS Oncogene: An Evolving Therapeutic Frontier

The Unmet Need in RAS-Driven Malignancies: A Historical Perspective

For over four decades, the RAS family of oncogenes—comprising KRAS, NRAS, and HRAS—has been recognized as a central driver of human cancer. Mutations in RAS genes are among the most frequent oncogenic events, occurring in approximately 21-30% of all human tumors and reaching particularly high prevalence in some of the most lethal malignancies, including pancreatic ductal adenocarcinoma (~95%), colorectal cancer (~50%), and non-small cell lung cancer (~30%).[1] These mutations typically lock the RAS protein in a constitutively active, GTP-bound "ON" state, leading to relentless downstream signaling through pathways like MAPK and PI3K, which in turn drive uncontrolled cell proliferation, survival, and differentiation.[4]

Despite its clear importance and high validation as a therapeutic target, the RAS protein was long deemed "undruggable".[5] This challenge stemmed from fundamental biochemical and structural properties. First, RAS proteins possess a remarkably smooth surface, lacking the deep, hydrophobic pockets that are traditionally exploited by small molecule inhibitors. Second, the affinity of RAS for its activating ligand, GTP, is in the picomolar range, and cellular concentrations of GTP are high, making the development of competitive inhibitors practically impossible.[5] These obstacles thwarted decades of drug discovery efforts, leaving a significant unmet medical need for millions of patients with RAS-driven cancers.

First-Generation Successes and Limitations: The KRAS G12C Story

The "undruggable" paradigm was finally broken with a landmark scientific breakthrough: the development of allele-specific covalent inhibitors targeting the KRAS G12C mutation. This specific mutation, which accounts for about 13% of non-small cell lung cancer (NSCLC) cases, creates a unique cysteine residue that can be targeted by a covalent warhead.[8] This discovery led to the development and subsequent FDA approval of sotorasib (Lumakras) and adagrasib (Krazati), the first-ever direct RAS inhibitors to reach the clinic.[9]

The approval of these agents was a watershed moment, definitively proving that direct RAS inhibition was clinically achievable and providing a new standard of care for a subset of patients. However, the initial excitement has been tempered by the clear limitations of this first-generation approach. The most significant limitation is their narrow scope; they are only effective against the KRAS G12C mutation, leaving the vast majority of patients with other RAS mutations (such as G12D, G12V, and Q61X) without a targeted therapy.[15] Furthermore, even in the targeted G12C population, clinical efficacy has been modest in certain tumor types, such as colorectal cancer (CRC), compared to NSCLC.[4]

Most critically, the durability of response to KRAS G12C inhibitors is limited by the rapid emergence of both intrinsic and acquired resistance.[10] Extensive research has revealed a complex landscape of resistance mechanisms. These include "on-target" resistance, where secondary mutations arise in the KRAS gene itself (e.g., at codons Y96, R68, H95) that prevent the drug from binding, and "off-target" resistance, where cancer cells bypass the inhibited KRAS G12C by reactivating the MAPK pathway through other means. Common bypass mechanisms involve the amplification of upstream receptor tyrosine kinases (RTKs) like EGFR, activating mutations in other RAS isoforms (NRAS) or downstream effectors (BRAF, MEK), or loss-of-function mutations in tumor suppressors like NF1 and PTEN.[16]

The Imperative for Pan-RAS Inhibition: Addressing a Wider Mutational Spectrum and Acquired Resistance

The clinical experience with KRAS G12C inhibitors has clearly illuminated the path forward. While validating the target, their shortcomings created an urgent need for next-generation therapies capable of addressing a broader spectrum of RAS mutations and overcoming the challenge of acquired resistance. This has given rise to the development of pan-RAS and pan-KRAS inhibitors.[23]

A pan-RAS inhibitor, by definition, is designed to inhibit multiple RAS isoforms (KRAS, NRAS, HRAS) and a wide array of their oncogenic mutations (e.g., G12X, G13X, Q61X). This approach dramatically expands the addressable patient population beyond the confines of a single allele. More importantly, it offers a compelling strategic rationale for tackling resistance. A key mechanism of resistance to allele-specific inhibitors is the reactivation of wild-type RAS isoforms, which can then continue to drive downstream signaling. A pan-RAS inhibitor, by targeting both mutant and wild-type RAS, is hypothesized to be able to block this escape route, potentially leading to more durable responses.[27]

This broader mechanism, however, introduces its own significant challenge: the therapeutic window. Normal, healthy cells throughout the body rely on wild-type RAS signaling for essential functions. An inhibitor that blocks all RAS activity without differentiation could lead to unacceptable toxicity.[6] Early genetically engineered mouse models where RAS was completely ablated were highly toxic, raising concerns about the feasibility of pan-RAS inhibition in the clinic.[30] However, more recent preclinical work suggests that pharmacologic inhibition may not equate to complete genetic ablation, and that tumor cells exhibit a state of "oncogene addiction," rendering them exquisitely sensitive to RAS pathway disruption in a way that normal cells are not.[31] Therefore, the central challenge for any pan-RAS inhibitor, including JYP-0015, is to demonstrate a sufficient therapeutic index in human trials—achieving potent anti-tumor activity while maintaining a manageable safety profile. The success of this new class of drugs will hinge on their ability to selectively exploit the dependencies of cancer cells while sparing the essential functions of normal tissues.

II. JYP-0015 (ERAS-0015): Profile of a Novel Investigational Agent

Pharmacological and Development Profile

JYP-0015 is an orally bioavailable small molecule being developed as a pan-RAS inhibitor for the treatment of solid tumors.[23] The compound was originally discovered and developed by Guangzhou JOYO Pharma Co., Ltd. (also referred to as Joyo Pharmatech), a pharmaceutical technology company based in Guangzhou, China.[23] Founded in 2017, JOYO Pharma has established R&D centers in Guangzhou, Shanghai, and Hangzhou and focuses on developing First-in-Class (FIC) and Best-in-Class (BIC) drugs for oncology, autoimmune disorders, and metabolic and infectious diseases.[34] The company's pipeline includes programs in various stages of development, from preclinical candidates to Phase III assets.[34]

In a significant strategic move, Erasca, Inc., a clinical-stage precision oncology company, acquired the exclusive rights to develop and commercialize JYP-0015 worldwide, with the exception of mainland China, Hong Kong, and Macau.[37] Within Erasca's pipeline, the compound is designated as ERAS-0015. This licensing agreement is a cornerstone of Erasca's corporate strategy, which is now singularly focused on targeting the RAS/MAPK pathway.

A Differentiated Mechanism: Pan-RAS Inhibition via Molecular Glue-Induced Ternary Complex Formation

JYP-0015 represents a novel therapeutic modality known as a "molecular glue".[27] Unlike traditional inhibitors that block an enzyme's active site, molecular glues function by inducing or stabilizing a novel protein-protein interaction that would not otherwise occur with high affinity. These small molecules create a new interaction surface on one protein, enabling it to bind to a second protein, thereby forming a stable three-part, or ternary, complex.[7] This mechanism is particularly powerful for targeting proteins like RAS that have been considered "undruggable" due to their smooth, featureless surfaces.

The specific mechanism of JYP-0015 involves several key steps:

  1. Targeting the Active State: JYP-0015 is designed to target RAS proteins when they are in their active, GTP-bound "ON" state. This is a critical distinction from first-generation KRAS G12C inhibitors, which bind to the inactive, GDP-bound "OFF" state.[27] By targeting the active conformation, JYP-0015 aims to directly shut down the source of the oncogenic signal.
  2. Recruiting a Presenter Protein: The molecular glue first binds to an abundant intracellular protein, Cyclophilin A (CypA).[27]
  3. Ternary Complex Formation: The newly formed JYP-0015-CypA complex presents a composite surface that is now complementary to the surface of the active RAS protein. This enables the formation of a stable ternary complex: RAS(ON)–JYP0015–CypA.[27]
  4. Inhibition of Downstream Signaling: The formation of this ternary complex acts as a steric block, physically preventing the active RAS protein from binding to and activating its downstream effectors, most notably the RAF kinases. This effectively shuts down the oncogenic signaling cascade through the RAS/MAPK pathway.[27]

This innovative mechanism circumvents the historical challenges of direct RAS inhibition by creating a new, druggable interface on the RAS protein through the induced proximity of CypA.

The Role of Cyclophilin A (CypA) as a Presenter Protein

The function of JYP-0015 is critically dependent on its interaction with Cyclophilin A (CypA). CypA is a highly conserved and ubiquitously expressed intracellular protein belonging to the immunophilin family, known for its peptidyl-prolyl cis-trans isomerase (PPIase) activity, which assists in protein folding.[54]

The relevance of CypA in this mechanism extends beyond its role as a simple scaffold. CypA is frequently overexpressed in a wide range of human cancers, including gastric, breast, colorectal, liver, and lung cancers.[56] Its overexpression has been functionally linked to the promotion of tumor cell proliferation, survival, metastasis, and resistance to therapy, often through its interaction with the cell surface receptor CD147 to activate oncogenic signaling pathways like PI3K/AKT and MAPK/ERK.[55]

In the context of JYP-0015's mechanism, CypA serves as the "presenter protein" that is co-opted by the molecular glue. This relationship may confer a degree of tumor selectivity. Since cancer cells often have higher levels of CypA than normal cells, the formation of the inhibitory RAS–JYP0015–CypA complex could theoretically occur at a higher rate within the tumor. This could lead to more profound RAS pathway inhibition in malignant cells compared to healthy tissues, potentially contributing to a favorable therapeutic window. This shared mechanism of leveraging CypA as a presenter protein is also employed by other leading pan-RAS inhibitors in development, such as daraxonrasib (RMC-6236), establishing this as a key emerging strategy in the field.[25]

III. Preclinical Validation and Competitive Positioning

Analysis of In Vitro and In Vivo Antitumor Activity (AACR 2025 Data)

Erasca, Inc. unveiled a significant body of preclinical data for ERAS-0015 at the American Association for Cancer Research (AACR) Annual Meeting in 2025, providing the first public evidence to support its potential as a best-in-class therapeutic.[53] The results demonstrated that ERAS-0015 possesses potent antitumor activity across a wide range of preclinical models.

In vitro studies showed that the compound effectively inhibited the proliferation of a diverse panel of cancer cell lines. These cell lines represented various tumor histologies and harbored a spectrum of different RAS mutations, validating the "pan-RAS" activity of the agent.[53]

The promising in vitro results were further substantiated by robust in vivo activity. In multiple xenograft models using RAS-mutant cancer cells, administration of ERAS-0015 as a monotherapy led to significant tumor growth inhibition.[53] Importantly, the data also highlighted promising activity when ERAS-0015 was used in combination with other therapeutic agents, a critical finding that points toward future clinical strategies aimed at producing more durable responses and overcoming resistance. This strong preclinical evidence package formed the basis for advancing ERAS-0015 into clinical development.

Pharmacokinetic and Pharmacodynamic (PK/PD) Profile

A key component of the preclinical data package for ERAS-0015 relates to its favorable drug-like properties. Studies assessing its absorption, distribution, metabolism, and excretion (ADME) and pharmacokinetic (PK) profile across multiple animal species were positive.[27] Two characteristics were particularly emphasized in the data presented at AACR 2025. First, ERAS-0015 demonstrated a longer residence time, suggesting that the inhibitory ternary complex it forms is highly stable, potentially leading to a more sustained blockade of RAS signaling after each dose. Second, the compound showed preferential distribution into tumor tissues compared to other tissues.[53] Together, these properties suggest that ERAS-0015 may be able to achieve robust and durable anti-tumor effects at lower systemic concentrations, which could translate into an improved safety and tolerability profile in patients.

Head-to-Head Preclinical Comparison: Benchmarking Against the Pan-RAS Landscape

In the competitive landscape of pan-RAS inhibitors, the most advanced asset and therefore the primary benchmark for ERAS-0015 is daraxonrasib (RMC-6236), which is being developed by Revolution Medicines and is already in late-stage clinical trials.[25] To establish a "best-in-class" profile, Erasca conducted head-to-head preclinical studies comparing ERAS-0015 with RMC-6236.

The results of these comparative studies form the central pillar of Erasca's investment thesis for the drug. The data revealed two key points of differentiation:

  1. Superior Cyclophilin A Binding: ERAS-0015 demonstrated 8- to 21-fold greater binding affinity to Cyclophilin A (CypA) than RMC-6236.[53] Since both drugs rely on forming a ternary complex with CypA and RAS, a stronger interaction with the presenter protein is a critical first step in the mechanism of action.
  2. Greater Potency: This enhanced binding affinity was shown to translate directly into greater biological potency. Erasca reported that ERAS-0015 exhibited approximately 5-fold greater potency in RAS inhibition and achieved comparable or superior in vivo antitumor activity at significantly lower doses than RMC-6236.[27]

These preclinical claims are fundamental to the strategic positioning of ERAS-0015. In a field where being first to market is a significant advantage, a "fast-follower" must convincingly demonstrate superiority. The biochemical argument for ERAS-0015 is that its higher affinity for CypA leads to more efficient formation of the inhibitory ternary complex, resulting in more potent RAS inhibition. If this biochemical advantage translates into a clinically meaningful benefit—either through superior efficacy at a comparable dose or equivalent efficacy at a lower, safer dose—it could allow ERAS-0015 to overtake its competitors. The validation of this claim in human clinical trials is therefore the most critical objective for the program.

Furthermore, the demonstration of strong preclinical activity in combination settings is not merely an ancillary finding but a core element of the drug's value proposition. The history of targeted oncology, particularly in pathways prone to feedback reactivation like the RAS/MAPK cascade, has consistently shown that monotherapy is rarely a durable solution.[22] Resistance is an expected outcome. Therefore, preclinical data showing that a drug works well in combination with other agents, such as immunotherapies or other MAPK pathway inhibitors, is a crucial de-risking factor.[3] It provides a clear roadmap for future development and addresses the inevitable challenge of acquired resistance from the outset.

IV. Clinical Development Pathway: The STAR/AURORAS-1 Trial

Study Design and Objectives (NCT06895031)

The first-in-human clinical trial for JYP-0015 is a Phase I/II, multi-center, open-label study officially titled, "A Multi-center, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of JYP0015 in Advanced Solid Tumors With RAS Mutation".[23] This trial is also referred to by its study identifiers, STAR and AURORAS-1.[32] The study employs a two-part design common for early-phase oncology trials, aiming to seamlessly transition from safety evaluation to efficacy exploration.

  • Phase I (Dose Escalation): The primary objective of the initial phase is to establish a safe and tolerable dose of JYP-0015 monotherapy. This will be achieved by enrolling small cohorts of patients at escalating dose levels. The key goals are to assess the safety and tolerability profile, characterize the pharmacokinetics (PK), and ultimately determine the Maximum Tolerated Dose (MTD) and/or the Recommended Dose for Expansion (RD) that will be used in the next phase of the study.[24]
  • Phase II (Indication Expansion): Once the RD is established, the trial will expand to enroll larger cohorts of patients into specific disease-specific arms. The primary goal of this phase is to evaluate the anti-tumor activity and therapeutic potential of JYP-0015 at the selected dose. The study will assess both efficacy and safety within four predefined cohorts, representing major areas of unmet need in RAS-driven cancers [24]:
  • Cohort A: Pancreatic ductal adenocarcinoma (PDAC)
  • Cohort B: Non-small cell lung cancer (NSCLC)
  • Cohort C: Colorectal cancer (CRC)
  • Cohort D: Other advanced solid tumors harboring qualifying RAS mutations

Target Patient Population: Defining the Scope of RAS-Mutant Solid Tumors

The trial is designed to enroll patients with a broad range of advanced solid tumors, contingent on the presence of a specific RAS mutation. The eligibility criteria are designed to select for a population that has exhausted standard therapies and has a molecular profile that makes them suitable candidates for a pan-RAS inhibitor.

Key Inclusion Criteria:

  • Age and Performance Status: Patients must be between 18 and 75 years of age with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, indicating they are fully ambulatory and capable of self-care.[23]
  • Tumor Type and Mutation Status: Patients must have histologically or pathologically confirmed advanced solid tumors. Critically, molecular testing must have identified a nonsynonymous mutation in one of the three RAS genes (KRAS, NRAS, or HRAS) at specific, well-known oncogenic codons: 12, 13, 61, 117, or 146.[23]
  • Prior Treatment: Enrolled patients must have experienced disease progression or been intolerant to adequate standard-of-care treatments, positioning JYP-0015 as a therapy for a relapsed/refractory population.[23]
  • Organ Function: Patients are required to have adequate organ function, as assessed by standard laboratory tests, to ensure they can tolerate the investigational therapy.[23]

Key Exclusion Criteria:

  • Central Nervous System (CNS) Metastases: Patients with active, untreated, or unstable brain metastases are excluded. However, patients with previously treated and clinically stable CNS metastases may be eligible.[23]
  • Gastrointestinal Conditions: Any GI disorder that could interfere with the administration or absorption of an oral drug is exclusionary. This includes dysphagia, malabsorption syndromes, and chronic inflammatory bowel diseases like Crohn's disease or ulcerative colitis.[23]
  • Cardiac Conditions: Patients with significant cardiovascular disease, defined as New York Heart Association (NYHA) functional class II or higher congestive heart failure or a left ventricular ejection fraction (LVEF) below 50%, are excluded.[23]

Endpoints and Timelines

The trial utilizes distinct endpoints for its two phases to systematically evaluate safety and then efficacy.

  • Primary Endpoints:
  • In the Phase I dose-escalation portion, the primary endpoint is safety, measured by the number of participants experiencing Dose-Limiting Toxicities (DLTs) during the initial 21-day treatment cycle. The incidence and severity of all Treatment-Emergent Adverse Events (TEAEs) will also be closely monitored.[23]
  • In the Phase II indication-expansion portion, the primary endpoint shifts to efficacy, measured as the Overall Response Rate (ORR) as assessed by the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).[23]
  • Secondary Endpoints:
  • Key secondary endpoints include pharmacokinetic measures such as Maximum Observed Blood Concentration (Cmax​) and Time to Reach Maximum Blood Concentration (Tmax​) of JYP-0015. Efficacy measures include Duration of Response (DOR) and Time to Response (TTR).[23]
  • Timelines and Status:
  • As of March 2025, the trial status was listed as "Not yet recruiting".[33]
  • Erasca received Investigational New Drug (IND) clearance from the FDA for ERAS-0015 in May 2025.[28]
  • The company has guided that initial monotherapy data from the Phase I portion of the AURORAS-1 trial is expected in 2026.[28] This data readout will be a critical catalyst for the program and for Erasca.

The table below consolidates the key parameters of this pivotal clinical trial.

Trial ParameterDetails
Official TitleA Multi-center, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of JYP0015 in Advanced Solid Tumors With RAS Mutation 23
IdentifiersNCT06895031; STAR; AURORAS-1 24
SponsorGuangzhou JOYO Pharma Co., Ltd. (Erasca, Inc. is the licensee) 23
Phase & StatusPhase I/II; Not Yet Recruiting (as of March 2025) 23
Study DesignOpen-label, multicenter, two-part study: Phase I (dose escalation) followed by Phase II (indication expansion) 24
Target PopulationPatients aged 18-75 with advanced or metastatic solid tumors who have progressed on standard therapy and harbor a documented mutation in KRAS, NRAS, or HRAS (codons 12, 13, 61, 117, or 146) 23
Key Inclusion CriteriaECOG performance status 0-1; adequate organ function 23
Key Exclusion CriteriaUnstable CNS metastases; significant GI disorders affecting absorption; significant cardiac impairment (LVEF <50%) 23
InterventionJYP-0015 (ERAS-0015) administered as an oral tablet 23
Phase I Primary EndpointsIncidence of Dose-Limiting Toxicities (DLTs); Safety and Tolerability; Determination of MTD/RD 23
Phase II Primary EndpointOverall Response Rate (ORR) per RECIST v1.1 23
Key Secondary EndpointsPharmacokinetics (Cmax​, Tmax​); Duration of Response (DOR); Time to Response (TTR) 23
Estimated Enrollment210 participants 23
Key TimelinesIND cleared May 2025; Initial Phase 1 monotherapy data expected in 2026 28

V. Corporate Strategy and Market Landscape

The Erasca-Joyo Licensing Agreement: A Strategic Deep-Dive

In May 2024, Erasca, Inc. fundamentally reshaped its pipeline and corporate strategy by entering into an exclusive licensing agreement with Guangzhou JOYO Pharma for two preclinical RAS-targeting assets: JYP-0015 (now ERAS-0015), a pan-RAS molecular glue, and a pan-KRAS inhibitor, ERAS-4001.[37] This transaction is central to understanding Erasca's current focus and future trajectory.

The terms of the agreement for ERAS-0015 reflect a structure common for early-stage assets, balancing upfront investment with long-term, success-based payments. Erasca secured the exclusive worldwide rights to develop and commercialize the compound, excluding mainland China, Hong Kong, and Macau, for a one-time upfront cash payment of $12.5 million. The deal is heavily back-loaded, with potential future payments of up to $176.5 million contingent upon the achievement of specific development, regulatory, and commercialization milestones. Additionally, Joyo is entitled to receive low- to mid-single-digit percentage royalties on future net sales. The agreement also includes an option for Erasca to expand its territory to be fully worldwide by making an additional one-time payment, the amount of which depends on the timing of the election relative to clinical development progress.[38] This structure allowed Erasca to acquire a high-potential, albeit preclinical, asset in a capital-efficient manner, preserving the majority of its financial resources for the expensive clinical development phase. It represents a shared-risk model where the ultimate value for the originator, Joyo, is highly dependent on Erasca's execution.

Erasca's Pipeline Prioritization: A Singular Focus on the RAS/MAPK Pathway

The in-licensing of the RAS-targeting franchise from Joyo was not merely an addition to Erasca's pipeline; it was a catalyst for a complete strategic realignment. Erasca's stated mission is to "erase cancer" by developing therapies that comprehensively shut down the RAS/MAPK pathway, one of the most commonly mutated signaling cascades in oncology.[60]

Following the acquisition of ERAS-0015 and ERAS-4001, the company conducted a strategic review that resulted in the deprioritization of its previous lead clinical asset, the pan-RAF inhibitor naporafenib. Erasca announced it would seek partnership opportunities for the naporafenib program, which had already advanced into a pivotal Phase 3 trial, to focus its internal resources and capital on accelerating the development of its new RAS-targeting assets.[28] This decisive pivot underscores the company's profound belief in the transformative potential of ERAS-0015 and ERAS-4001. It transformed Erasca from a company with a broader MAPK pathway focus into one with a highly concentrated, high-conviction bet on direct RAS inhibition. This strategic concentration, while increasing the risk associated with these two specific programs, also sharpens the company's focus and aligns its resources with what it perceives to be the highest-impact opportunities.

The table below illustrates Erasca's current pipeline, highlighting the central role of the newly acquired RAS-targeting franchise.

Program NameTarget / MechanismHighest StageKey IndicationsOriginator / PartnerStrategic Status
ERAS-0015Pan-RAS Molecular GluePhase I/IIRAS-mutant Solid TumorsGuangzhou JOYO PharmaPrioritized
ERAS-4001Pan-KRAS InhibitorPhase I (Planned)KRAS-mutant Solid TumorsGuangzhou JOYO PharmaPrioritized
NaporafenibPan-RAF InhibitorPhase IIINRAS-mutant MelanomaNovartisSeeking Partnership
ERAS-12EGFR D2/D3 Bispecific AntibodyPreclinicalEGFR & RAS/MAPK Altered TumorsEmerge Life SciencesDiscovery/Preclinical
ERAS-007ERK1/2 InhibitorPreclinicalRAS/MAPK-altered Tumors-Combination Partner
ERAS-601SHP2 InhibitorPreclinicalRAS/MAPK-altered Tumors-Combination Partner
ERAS-801EGFR InhibitorDeprioritizedRecurrent Glioblastoma-Deprioritized

Table compiled from sources.[26]

Competitive Intelligence: Mapping the Pan-RAS and Pan-KRAS Inhibitor Space

Erasca and JYP-0015 are entering a dynamic and increasingly competitive field. While the target space is vast, several other companies are aggressively pursuing pan-RAS and pan-KRAS inhibition strategies.

The undisputed leader in this specific niche is Revolution Medicines. Their portfolio includes daraxonrasib (RMC-6236), a pan-RAS(ON) molecular glue that is already in Phase 3 trials for both NSCLC and pancreatic cancer, and RMC-7977, another multi-selective RAS(ON) inhibitor.[25] The advanced clinical status of daraxonrasib establishes it as the primary benchmark against which all other pan-RAS inhibitors, including ERAS-0015, will be measured.

Other major pharmaceutical and biotech companies are also active in the broader RAS-targeting space, including Lilly, Pfizer, BeiGene, and BridgeBio Oncology.[26] Additionally, several smaller companies and academic groups are developing novel pan-RAS inhibitors, such as the ADT-007/ADT-1004 program, which also shows promising preclinical activity and a unique mechanism of action.[99]

This competitive context frames Erasca's approach as a "fast-follower" strategy. The company is not aiming to be the first to market with a pan-RAS inhibitor. Instead, its strategy is predicated on being "best-in-class." This entire corporate bet is founded on the preclinical data suggesting that ERAS-0015 possesses superior biochemical properties—namely, higher affinity and potency—compared to the frontrunner, RMC-6236. The 2026 initial data readout from the AURORAS-1 trial will therefore be a pivotal, make-or-break event for the company, as it will provide the first human data to either support or refute this best-in-class hypothesis.

VI. Future Outlook: Combination Strategies and Market Potential

The Rationale for Combination Therapy: Overcoming Resistance and Enhancing Efficacy

The clinical experience with targeted therapies in oncology, and particularly within the RAS/MAPK pathway, has delivered a consistent and powerful lesson: monotherapy is rarely sufficient for durable disease control. Cancer cells possess a remarkable capacity for adaptation, and when a single signaling node is blocked, they often find alternative routes to survive and proliferate. This phenomenon, known as adaptive or acquired resistance, is driven by mechanisms such as feedback loop reactivation and the activation of parallel bypass pathways.[19]

For RAS inhibitors, this is a central challenge. Inhibition of RAS can lead to a feedback-driven reactivation of upstream receptor tyrosine kinases (RTKs) like EGFR, which can then re-stimulate the MAPK pathway, blunting the effect of the inhibitor.[4] Consequently, the long-term vision for RAS-targeted therapy does not lie in monotherapy but in the development of intelligent, rationally designed combination strategies. The goal of these combinations is to create a more comprehensive and durable blockade of oncogenic signaling by targeting the pathway at multiple points simultaneously or by attacking the cancer through orthogonal mechanisms. Preclinical data overwhelmingly supports this approach, and it is the clear path forward for JYP-0015 and the entire field.[3]

Preclinical Evidence for Key Combination Strategies

  • Combination with Immunotherapy (e.g., anti-PD-1): A compelling body of evidence indicates that oncogenic RAS signaling actively shapes the tumor microenvironment to be immunosuppressive. RAS-driven tumors often secrete cytokines and chemokines that recruit suppressive immune cells (like myeloid-derived suppressor cells and regulatory T-cells) while excluding cytotoxic T-cells. Furthermore, RAS signaling can lead to the upregulation of immune checkpoint proteins like PD-L1 on cancer cells, helping them evade immune destruction.[22] Preclinical studies have shown that inhibiting KRAS can reverse many of these effects, leading to increased T-cell infiltration and a more "inflamed" tumor microenvironment that is susceptible to immune checkpoint inhibitors (ICIs) like anti-PD-1 antibodies. In multiple mouse models, combining KRAS inhibitors with ICIs has led to synergistic and sometimes curative responses, providing a strong rationale for this combination in the clinic.[22] Erasca has already generated supportive preclinical data for its pan-KRAS inhibitor, ERAS-4001, in combination with an anti-PD-1 agent, demonstrating robust tumor growth inhibition.[53]
  • Combination with MAPK Pathway Inhibitors: A second major strategy is "vertical inhibition," which involves combining a RAS inhibitor with an agent that targets a downstream node in the same pathway, such as a MEK or RAF inhibitor. The rationale is to prevent the reactivation of the pathway that can occur as a feedback response to single-agent inhibition. By blocking the pathway at two distinct points, a deeper and more sustained shutdown of oncogenic signaling can be achieved.[15] This approach has shown promise in numerous preclinical models and is being actively explored in clinical trials for various RAS and RAF inhibitors.

Analyst Assessment: Projecting the Clinical and Commercial Trajectory of JYP-0015

  • Market Potential: The addressable market for a safe and effective pan-RAS inhibitor is one of the largest in oncology. Given that RAS mutations are implicated in a high percentage of pancreatic, colorectal, and lung cancers—three of the most common and deadly malignancies—a successful drug in this class could achieve blockbuster status with annual sales in the multi-billions of dollars.
  • Clinical and Commercial Trajectory: The clinical path for JYP-0015 will begin with establishing monotherapy safety and identifying a signal of efficacy in the ongoing AURORAS-1 trial. Success in this initial phase will be a major value inflection point. However, the long-term strategy will almost certainly involve a rapid pivot to combination studies. The competitive dynamic in this space is not a simple race to first monotherapy approval, but rather a more complex race to establish the most effective combination regimen that can become a new standard of care. The ultimate commercial success of JYP-0015 will depend on Erasca's ability to identify the right tumor types, the right patient populations (potentially defined by co-mutations), and the right combination partners to deliver a clear and compelling clinical benefit over both existing standards of care and competing RAS inhibitors.

Key Risks and Potential Mitigating Factors

Despite the significant promise, the development of JYP-0015 is subject to several key risks:

  1. Clinical Translation Risk: The most significant risk is that the compelling preclinical profile of JYP-0015—particularly its superior potency compared to its main competitor—does not translate into a differentiated efficacy or safety profile in human clinical trials. The complexity of human biology and tumor heterogeneity means that preclinical advantages do not always predict clinical success.
  2. Safety and Tolerability Risk: As a pan-RAS inhibitor that targets both mutant and wild-type isoforms, on-target toxicity in healthy tissues remains a primary concern. While preclinical models have been encouraging, the true safety profile and therapeutic window will only be revealed in the Phase I study. Managing potential toxicities such as rash and gastrointestinal side effects will be critical.
  3. Competitive Risk: The field of RAS inhibition is advancing at an extraordinary pace. Revolution Medicines is significantly ahead in clinical development with RMC-6236. Any delays in the execution of the AURORAS-1 trial or subsequent studies could cede further ground to competitors, making it more difficult for JYP-0015 to gain a market foothold, even with a potentially superior profile.

In conclusion, JYP-0015 (ERAS-0015) is a highly promising, next-generation cancer therapeutic with a differentiated mechanism and a compelling preclinical data package. Its development represents a high-risk, high-reward endeavor for Erasca, Inc., which has staked its corporate future on the success of this asset and its companion, ERAS-4001. The initial clinical data readout in 2026 will be a critical moment, providing the first glimpse into whether its best-in-class preclinical profile can be translated into a paradigm-shifting therapy for patients with RAS-mutant cancers. The long-term success of the program will ultimately be defined by its performance in rational, well-designed combination therapies that can overcome the formidable challenge of therapeutic resistance.

Works cited

  1. Targeting RAS mutants in malignancies: successes, failures, and reasons for hope-Bohrium, accessed June 19, 2025, https://www.bohrium.com/paper-details/targeting-ras-mutants-in-malignancies-successes-failures-and-reasons-for-hope/864985003052761329-9604
  2. The current state of the art and future trends in RAS-targeted cancer therapies, accessed June 19, 2025, https://www.researchgate.net/publication/362983899_The_current_state_of_the_art_and_future_trends_in_RAS-targeted_cancer_therapies
  3. More to the RAS Story: KRASG12C Inhibition, Resistance Mechanisms, and Moving Beyond KRASG12C - ASCO Publications, accessed June 19, 2025, https://ascopubs.org/doi/10.1200/EDBK_351333
  4. Small molecular inhibitors for KRAS-mutant cancers - Frontiers, accessed June 19, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1223433/full
  5. RAS: Targeting the Impossible - Crown Bioscience Blog, accessed June 19, 2025, https://blog.crownbio.com/targeting-ras-oncology
  6. New Ways of Targeting Ras - McCormick Lab @ UCSF, accessed June 19, 2025, https://mccormicklab.ucsf.edu/new-ways-targeting-ras
  7. Gluing GAP to RAS Mutants: A New Approach to an Old Problem in ..., accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10932042/
  8. The current state of the art and future trends in RAS-targeted cancer therapies, accessed June 19, 2025, https://searchit.libraries.wsu.edu/discovery/fulldisplay?docid=cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9412785&context=PC&vid=01ALLIANCE_WSU:WSU&lang=en&search_scope=WSU_everything&adaptor=Primo%20Central&tab=default_tab&query=creator%2Cequals%2C%20WONG%2C%20Kwok-Kin&offset=0
  9. The current state of the art and future trends in RAS-targeted cancer therapies - PubMed, accessed June 19, 2025, https://pubmed.ncbi.nlm.nih.gov/36028717/
  10. Mechanisms of Resistance to KRASG12C Inhibitors - PMC - PubMed Central, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7795113/
  11. Identification and Characterization of Novel Small-Molecule Enhancers of the CUL3LZTR1 E3 Ligase KRAS Complex - ACS Publications, accessed June 19, 2025, https://pubs.acs.org/doi/10.1021/acschembio.4c00077
  12. Management of KRAS-Mutated Non–Small Cell Lung Cancer - Hematology & Oncology, accessed June 19, 2025, https://www.hematologyandoncology.net/archives/march-2024/management-of-kras-mutated-non-small-cell-lung-cancer/
  13. Sotorasib Superiority Vs Standard of Care Docetaxel in Previously Treated KRAS G12C–Mutant NSCLC - CancerNetwork, accessed June 19, 2025, https://www.cancernetwork.com/view/sotorasib-superiority-vs-standard-of-care-docetaxel-in-previously-treated-kras-g12c-mutant-nsclc
  14. Sotorasib A New Standard of Care for Second- or Third-Line Treatment of KRAS G12C–Mutated NSCLC - The ASCO Post, accessed June 19, 2025, https://ascopost.com/issues/november-10-2022/sotorasib-a-new-standard-of-care-for-second-or-third-line-treatment-of-kras-g12c-mutated-nsclc/
  15. KRAS G12C inhibitor combination therapies: current evidence and challenge - PMC, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11097198/
  16. Advances and Challenges in RAS Signaling Targeted Therapy in Leukemia | Molecular Cancer Therapeutics - AACR Journals, accessed June 19, 2025, https://aacrjournals.org/mct/article/24/1/33/750651/Advances-and-Challenges-in-RAS-Signaling-Targeted
  17. Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer - Frontiers, accessed June 19, 2025, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.787585/full
  18. Mechanisms of Resistance to KRASG12C Inhibitors - ResearchGate, accessed June 19, 2025, https://www.researchgate.net/publication/348256885_Mechanisms_of_Resistance_to_KRASG12C_Inhibitors
  19. Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer - PMC, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11410594/
  20. Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition - JCI, accessed June 19, 2025, https://www.jci.org/articles/view/155523
  21. Mechanisms of Acquired Resistance to KRAS G12C Inhibition in Patients With Cancer, accessed June 19, 2025, https://ascopost.com/news/july-2021/mechanisms-of-acquired-resistance-to-kras-g12c-inhibition-in-patients-with-cancer/
  22. Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy - PMC, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10722141/
  23. Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS - Carebox Connect, accessed June 19, 2025, https://connect.careboxhealth.com/en-US/trial/listing/586457
  24. Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS (STAR) - ClinicalTrials.Veeva, accessed June 19, 2025, https://ctv.veeva.com/study/study-of-jyp0015-in-patients-with-advanced-solid-tumors-harboring-specific-mutations-in-ras
  25. RASolute 302 Trial for KRAS and Other RAS Mutations Recruiting at Multiple Sites, accessed June 19, 2025, https://letswinpc.org/research/kras-trial-recruiting-worldwide/
  26. Erasca enters its pan-RAS era | ApexOnco - Clinical Trials news and analysis, accessed June 19, 2025, https://www.oncologypipeline.com/apexonco/erasca-enters-its-pan-ras-era
  27. ERAS-0015 - Drug Targets, Indications, Patents - Synapse, accessed June 19, 2025, https://synapse.patsnap.com/drug/356f05e129104d99bf30f8a498eb9900
  28. Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway - GlobeNewswire, accessed June 19, 2025, https://www.globenewswire.com/news-release/2025/05/13/3080058/0/en/Erasca-Announces-Early-Clinical-Advancement-and-Prioritization-of-RAS-Targeting-Franchise-Coupled-with-More-than-3-Years-of-Projected-Cash-Runway.html
  29. Erasca Announces Early Clinical Advancement and Prioritization of ..., accessed June 19, 2025, https://investors.erasca.com/news-releases/news-release-details/erasca-announces-early-clinical-advancement-and-prioritization/
  30. Pan-RAS Inhibitor Shows Early, Deep Molecular Responses in PDAC - ASCO Daily News, accessed June 19, 2025, https://dailynews.ascopubs.org/do/pan-ras-inhibitor-shows-early-deep-molecular-responses-pdac
  31. RAS inhibitor 1 - THE OLIVE LABORATORY, accessed June 19, 2025, https://www.olivelab.org/ras-inhibitor-1.html
  32. JYP 0015 - AdisInsight - Springer, accessed June 19, 2025, https://adisinsight.springer.com/drugs/800081894
  33. JYP-0015 - MedPath, accessed June 19, 2025, https://trial.medpath.com/drug/4f1e7c79f66e382c
  34. Joyo Asset Profile | Preqin, accessed June 19, 2025, https://www.preqin.com/data/profile/asset/joyo/438233
  35. Joyo Pharma 2025 Company Profile: Valuation, Funding & Investors | PitchBook, accessed June 19, 2025, https://pitchbook.com/profiles/company/470861-20
  36. Guangzhou Jiayue Pharmaceutical Technology Co., Ltd. - Drug pipelines, Patents, Clinical trials - Patsnap Synapse, accessed June 19, 2025, https://synapse-patsnap-com.libproxy1.nus.edu.sg/organization/9568a527321e8dab80b9c8b571ecb5f0
  37. Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise, accessed June 19, 2025, https://investors.erasca.com/news-releases/news-release-details/erasca-announces-strategic-licensing-ras-targeting-franchise/
  38. 0001193125-24-140591 | 8-K | iXBRL Viewer | Erasca INC, accessed June 19, 2025, https://investors.erasca.com/node/8131/ixbrl-viewer
  39. Erasca doubles down on RAS | ApexOnco - Oncology Pipeline, accessed June 19, 2025, https://www.oncologypipeline.com/apexonco/erasca-doubles-down-ras
  40. Stick it to RAS: The Next Wave of Ras Therapeutics - Cytoskeleton, Inc., accessed June 19, 2025, https://www.cytoskeleton.com/december-newsletter-stick-it-to-ras-the-next-wave-of-ras-therapeutics
  41. Gluing GAP to RAS Mutants: A New Approach to an Old Problem in Cancer Drug Development - MDPI, accessed June 19, 2025, https://www.mdpi.com/1422-0067/25/5/2572
  42. Drug blocking cancer-driving RAS-PI3K pathway enters clinical trials | Frederick National Laboratory, accessed June 19, 2025, https://frederick.cancer.gov/news/drug-blocking-cancer-driving-ras-pi3k-pathway-enters-clinical-trials
  43. Eliminating oncogenic RAS: back to the future at the drawing board - PMC - PubMed Central, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9987992/
  44. Leveraging Structural and Computational Biology for Molecular Glue Discovery - PubMed, accessed June 19, 2025, https://pubmed.ncbi.nlm.nih.gov/39854250/
  45. Research status and analysis of molecular glue - BOC Sciences, accessed June 19, 2025, https://www.bocsci.com/resources/research-status-and-analysis-of-molecular-glue.html
  46. The Rise of Molecular Glues - ResearchGate, accessed June 19, 2025, https://www.researchgate.net/publication/348344166_The_Rise_of_Molecular_Glues
  47. Discovery of fully synthetic FKBP12-mTOR molecular glues - Chemical Science (RSC Publishing) DOI:10.1039/D4SC06917J, accessed June 19, 2025, https://pubs.rsc.org/en/content/articlehtml/2025/sc/d4sc06917j
  48. The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with A - AACR Journals, accessed June 19, 2025, https://aacrjournals.org/cancerdiscovery/article-pdf/doi/10.1158/2159-8290.CD-24-0139/3443678/cd-24-0139.pdf
  49. Molecular glue - Wikipedia, accessed June 19, 2025, https://en.wikipedia.org/wiki/Molecular_glue
  50. Molecular glue degrader for tumor treatment - Frontiers, accessed June 19, 2025, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1512666/full
  51. The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway w… - OUCI, accessed June 19, 2025, https://ouci.dntb.gov.ua/en/works/4z6g5WV4/
  52. A first-in-human study of IK-595, an oral MEK/RAF molecular glue, in patients with RAS- or RAF-altered advanced solid tumors. - ASCO Publications, accessed June 19, 2025, https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.TPS3185
  53. Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting - GlobeNewswire, accessed June 19, 2025, https://www.globenewswire.com/news-release/2025/04/29/3070761/0/en/Erasca-Presents-New-Preclinical-Data-Reinforcing-Best-in-Class-Potential-of-RAS-Targeting-Franchise-at-the-2025-AACR-Annual-Meeting.html
  54. Inhibitors of Cyclophilin A: Current and Anticipated Pharmaceutical Agents for Inflammatory Diseases and Cancers - MDPI, accessed June 19, 2025, https://www.mdpi.com/1420-3049/29/6/1235
  55. Cyclophilin A knockdown inhibits the proliferation and metastatic ability of AGS gastric cancer stem cells by downregulating CD147/STAT3/AKT/ERK and epithelial‑mesenchymal transition - Spandidos Publications, accessed June 19, 2025, https://www.spandidos-publications.com/10.3892/mmr.2024.13379
  56. pmc.ncbi.nlm.nih.gov, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11552246/#:~:text=CypA%20promotes%20cell%20proliferation,associated%20with%20its%20PPIase%20activity.
  57. Cyclophilin A/CD147 Interaction: A Promising Target for Anticancer Therapy - MDPI, accessed June 19, 2025, https://www.mdpi.com/1422-0067/23/16/9341
  58. Cyclophilin A: promising target in cancer therapy - PMC, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11552246/
  59. Cyclophilin A Function in Mammary Epithelium Impacts Jak2/Stat5 Signaling, Morphogenesis, Differentiation, and Tumorigenesis in the Mammary Gland | Cancer Research - AACR Journals, accessed June 19, 2025, https://aacrjournals.org/cancerres/article/doi/10.1158/0008-5472.CAN-17-2892/661270/p/Cyclophilin-A-Function-in-Mammary-Epithelium
  60. Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting, accessed June 19, 2025, https://investors.erasca.com/news-releases/news-release-details/erasca-presents-new-preclinical-data-reinforcing-best-class/
  61. Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236, accessed June 19, 2025, https://pubmed.ncbi.nlm.nih.gov/39586491
  62. Center for RAS Therapeutics Clinical Trials and Research - Dana-Farber Cancer Institute, accessed June 19, 2025, https://www.dana-farber.org/research/integrative-research/ras-therapeutics/clinical-trials-research
  63. Revolution sets sights on Phase III trial for pan-RAS inhibitor - Clinical Trials Arena, accessed June 19, 2025, https://www.clinicaltrialsarena.com/news/revolution-sets-sights-on-phase-iii-trial-for-pan-ras-inhibitor/
  64. Moving the Needle With Pan-RAS Inhibitors, Vaccines in Pancreatic Cancer, accessed June 19, 2025, https://www.cancernetwork.com/view/moving-the-needle-with-pan-ras-inhibitors-vaccines-in-pancreatic-cancer
  65. Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio, accessed June 19, 2025, https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-provides-clinical-updates-its-rason/
  66. Phase 1 Data Support Further Investigation of RMC-6236 in KRAS-Mutant NSCLC - OncLive, accessed June 19, 2025, https://www.onclive.com/view/phase-1-data-support-further-investigation-of-rmc-6236-in-kras-mutant-nsclc
  67. Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma, accessed June 19, 2025, https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-presents-updated-data-rmc-6236-monotherapy/
  68. Highlights from the 2025 AACR Annual Meeting - Let's Win Pancreatic Cancer, accessed June 19, 2025, https://letswinpc.org/research/research-highlights-2025-aacr-meeting/
  69. Exploring Zoldonrasib, Pan-RAS Inhibitors, and Future KRAS Therapies, accessed June 19, 2025, https://www.targetedonc.com/view/exploring-zoldonrasib-pan-ras-inhibitors-and-future-kras-therapies
  70. Targeting KRAS - PMC - PubMed Central, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11845254/
  71. Combining immunotherapy with KRAS inhibitor eliminates advanced KRAS-mutant pancreatic cancer in preclinical models, accessed June 19, 2025, https://www.mdanderson.org/newsroom/combining-immunotherapy-kras-inhibitor-eliminates-advanced-kras-mutant-pancreatic-cancer-preclinical-models.h00-159621012.html
  72. pan-KRAS inhib News - LARVOL Sigma, accessed June 19, 2025, https://sigma.larvol.com/moa.php?MoaId=1024626&tab=newstrac
  73. Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy - AACR Journals, accessed June 19, 2025, https://aacrjournals.org/clincancerres/article/29/24/5012/731670/Facts-and-Hopes-on-RAS-Inhibitors-and-Cancer
  74. Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors - GlobeNewswire, accessed June 19, 2025, https://www.globenewswire.com/news-release/2024/10/23/2967673/35186/en/Kura-Oncology-to-Present-New-Data-Supporting-Combination-of-KO-2806-with-KRAS-G12C-and-Pan-RAS-Inhibitors.html
  75. Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer, accessed June 19, 2025, https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-announces-publication-demonstrating-robust/
  76. KRAS G12C inhibitor combination therapies: current evidence and challenge, accessed June 19, 2025, https://www.researchgate.net/publication/380306490_KRAS_G12C_inhibitor_combination_therapies_current_evidence_and_challenge
  77. Combination of RAS inhibition and immunotherapy provides breakthrough for pancreatic cancer - News-Medical.net, accessed June 19, 2025, https://www.news-medical.net/news/20250314/Combination-of-RAS-inhibition-and-immunotherapy-provides-breakthrough-for-pancreatic-cancer.aspx
  78. Structural insights, regulation, and recent advances of RAS inhibitors in the MAPK signaling cascade: a medicinal chemistry perspective - PubMed Central, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11880839/
  79. Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers | PNAS, accessed June 19, 2025, https://www.pnas.org/doi/10.1073/pnas.2319492121
  80. Expanding the Reach of Precision Oncology by Drugging All KRAS ..., accessed June 19, 2025, https://aacrjournals.org/cancerdiscovery/article/12/4/924/689602/Expanding-the-Reach-of-Precision-Oncology-by
  81. Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11577641/
  82. Combined pan-RAF and MEK inhibition overcomes multiple resistance mechanisms to selective RAF inhibitors - PMC, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4674359/
  83. BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical Trial, accessed June 19, 2025, https://ir.springworkstx.com/news-releases/news-release-details/beigene-and-springworks-announce-presentation-preclinical-data/
  84. Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6, accessed June 19, 2025, https://aacrjournals.org/cancerres/article/82/18/3335/709024/Targeting-RAS-Mutant-Colorectal-Cancer-with-Dual
  85. Drugging the Undruggable: Advances on RAS Targeting in Cancer - MDPI, accessed June 19, 2025, https://www.mdpi.com/2073-4425/12/6/899
  86. Pipeline - Erasca, accessed June 19, 2025, https://www.erasca.com/pipeline/
  87. Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | TrialScreen, accessed June 19, 2025, https://app.trialscreen.org/trials/phase-1-2-jyp0015-patients-advanced-solid-tumors-harboring-specific-mutations-trial-nct06895031
  88. Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | MedPath, accessed June 19, 2025, https://trial.medpath.com/clinical-trial/dff8f6bb5a8eb331/jyp0015-ras-mutation-advanced-solid-tumors
  89. Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS - LARVOL, accessed June 19, 2025, https://clin.larvol.com/trial-detail/NCT06895031
  90. Form 8-K for Erasca INC filed 05/13/2025, accessed June 19, 2025, https://investors.erasca.com/static-files/91657444-7161-4999-816e-47af71144fec
  91. EX-99.1 - SEC.gov, accessed June 19, 2025, https://www.sec.gov/Archives/edgar/data/0001761918/000095017025070336/eras-ex99_1.htm
  92. Erasca Reports First Quarter 2025 Business Updates and Financial Results, accessed June 19, 2025, https://investors.erasca.com/news-releases/news-release-details/erasca-reports-first-quarter-2025-business-updates-and-financial/
  93. Erasca Reports First Quarter 2025 Business Updates and Financial Results, accessed June 19, 2025, https://investors.erasca.com/node/8666/pdf
  94. Study of JYP0015 in Patients With Advanced Solid Tumors - ClinConnect, accessed June 19, 2025, https://clinconnect.io/trials/NCT06895031
  95. Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting, accessed June 19, 2025, https://investors.erasca.com/news-releases/news-release-details/erasca-announces-three-poster-presentations-2025-aacr-annual/
  96. Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting, accessed June 19, 2025, https://www.globenewswire.com/news-release/2025/03/25/3049196/0/en/Erasca-Announces-Three-Poster-Presentations-at-the-2025-AACR-Annual-Meeting.html
  97. Erasca: Home, accessed June 19, 2025, https://www.erasca.com/
  98. Investors – Erasca, accessed June 19, 2025, https://investors.erasca.com/
  99. A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer | bioRxiv, accessed June 19, 2025, https://www.biorxiv.org/content/10.1101/2023.05.17.541233v4
  100. ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma - PMC, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11905721/
  101. Preclinical Development of a Novel Pan-RAS Inhibitor Against Relapsed/Refractory Multiple Myeloma | Blood | American Society of Hematology, accessed June 19, 2025, https://ashpublications.org/blood/article/144/Supplement%201/3263/533196/Preclinical-Development-of-a-Novel-Pan-RAS
  102. Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor models, accessed June 19, 2025, https://pubmed.ncbi.nlm.nih.gov/40060415/
  103. Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor models, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11888295/
  104. A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer - PubMed, accessed June 19, 2025, https://pubmed.ncbi.nlm.nih.gov/38328254/
  105. Abstract 3323: Novel Pan-RAS inhibitor ADT-007: A unique mechanism of antitumor selectivity in pancreatic and colorectal carcinoma models - AACR Journals, accessed June 19, 2025, https://aacrjournals.org/cancerres/article/84/6_Supplement/3323/739103/Abstract-3323-Novel-Pan-RAS-inhibitor-ADT-007-A
  106. A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10849544/
  107. Pan-RAS - Qualigen Therapeutics, accessed June 19, 2025, https://qlgntx.com/pipeline/ras/

Published at: June 19, 2025

This report is continuously updated as new research emerges.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy